Colorectal Diseases: Diagnosis, Treatment and Multidisciplinary Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 4266

Special Issue Editor


E-Mail Website
Guest Editor
Dept Diagnost Imaging, Pisa Univ Hosp, Via Paradisa 2, I-56124 Pisa, Italy
Interests: abdominal radiology; MRI; diffusion and perfusion MRI; oncologic imaging; liver; pancreas; biliary tract; rectal cancer; inflammatory bowel disease; liver transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Colorectal cancer (CRC) is the third most common cancer in men (10% of all cancers) and the second most common cause of cancer in women (9.2% of all cancers). As you are all aware, the liver is the most common metastatic site in CRC. Approximately 15–25% of CRC patients develop synchronous liver metastases, and another 20–25% of them develop metachronous metastases. As the title suggests, this Special Issue aims to address the most recent advancements in the diagnosis, treatment, and multidisciplinary management of CRC liver metastases.

Novel diagnostic approaches (in particular MRI with hepato-biliary contrast agents and diffusion-weighted imaging, intraoperative ultrasound, and PET-MRI) are now available, although they are not always routinely used in clinical practice. However, the correct timing and the respective role in the diagnostic management is very much debated, even in dedicated multidisciplinary teams.

Tumor biology is increasingly recognized as an important prognostic factor; hence, molecular profiling has a growing role in management planning. Although surgical resection is the only treatment modality for curative intent of CRC liver metastases, the most appropriate surgical approach is yet to be established.  Furthermore, new chemotherapy regimens have been introduced, and are often personalized for the individual patient.

The aim of Special Issue is to provide a collection of review articles and original contributions on the above-mentioned topics, with the intent of improving the quality of patients’ care.

Dr. Piero Boraschi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Colorectal cancer
  • Metastatic disease
  • Colorectal liver metastases
  • Chemotherapy
  • Surgery
  • Therapeutic response assessment
  • Biomarkers
  • Tumor regression grading
  • Computed tomography
  • MRI
  • PET
  • Intraoperative ultrasound
  • Multidisciplinary management

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

23 pages, 22591 KiB  
Systematic Review
The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review
by Okker D. Bijlstra, Maud M. E. Boreel, Sietse van Mossel, Mark C. Burgmans, Ellen H. W. Kapiteijn, Daniela E. Oprea-Lager, Daphne D. D. Rietbergen, Floris H. P. van Velden, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg, J. Sven D. Mieog and Lioe-Fee de Geus-Oei
Diagnostics 2022, 12(3), 715; https://doi.org/10.3390/diagnostics12030715 - 15 Mar 2022
Cited by 6 | Viewed by 3046
Abstract
(1) Background: Up to 50% of patients with colorectal cancer either have synchronous colorectal liver metastases (CRLM) or develop CRLM over the course of their disease. Surgery and thermal ablation are the most common local treatment options of choice. Despite development and improvement [...] Read more.
(1) Background: Up to 50% of patients with colorectal cancer either have synchronous colorectal liver metastases (CRLM) or develop CRLM over the course of their disease. Surgery and thermal ablation are the most common local treatment options of choice. Despite development and improvement in local treatment options, (local) recurrence remains a significant clinical problem. Many different imaging modalities can be used in the follow-up after treatment of CRLM, lacking evidence-based international consensus on the modality of choice. In this systematic review, we evaluated 18F-FDG-PET-CT performance after surgical resection, thermal ablation, radioembolization, and neoadjuvant and palliative chemotherapy based on current published literature. (2) Methods: A systematic literature search was performed on the PubMed database. (3) Results: A total of 31 original articles were included in the analysis. Only one suitable study was found describing the role of 18F-FDG-PET-CT after surgery, which makes it hard to draw a firm conclusion. 18F-FDG-PET-CT showed to be of additional value in the follow-up after thermal ablation, palliative chemotherapy, and radioembolization. 18F-FDG-PET-CT was found to be a poor to moderate predictor of pathologic response after neoadjuvant chemotherapy. (4) Conclusions: 18F-FDG-PET-CT is superior to conventional morphological imaging modalities in the early detection of residual disease after thermal ablation and in the treatment evaluation and prediction of prognosis during palliative chemotherapy and after radioembolization, and 18F-FDG-PET-CT could be considered in selected cases after neoadjuvant chemotherapy and surgical resection. Full article
Show Figures

Figure 1

Back to TopTop